230 related articles for article (PubMed ID: 34342126)
1. Small-Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery.
Li G; Sun B; Li Y; Luo C; He Z; Sun J
Small; 2021 Dec; 17(52):e2101460. PubMed ID: 34342126
[TBL] [Abstract][Full Text] [Related]
2. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery.
Kyu Shim M; Yang S; Sun IC; Kim K
Adv Drug Deliv Rev; 2022 Apr; 183():114177. PubMed ID: 35245568
[TBL] [Abstract][Full Text] [Related]
3. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
4. Dimeric prodrug-based nanomedicines for cancer therapy.
Li S; Shan X; Wang Y; Chen Q; Sun J; He Z; Sun B; Luo C
J Control Release; 2020 Oct; 326():510-522. PubMed ID: 32721523
[TBL] [Abstract][Full Text] [Related]
5. Probing the Superiority of Diselenium Bond on Docetaxel Dimeric Prodrug Nanoassemblies: Small Roles Taking Big Responsibilities.
Zuo S; Sun B; Yang Y; Zhou S; Zhang Y; Guo M; Sun M; Luo C; He Z; Sun J
Small; 2020 Nov; 16(45):e2005039. PubMed ID: 33078579
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
7. Tailoring carrier-free nanocombo of small-molecule prodrug for combinational cancer therapy.
Li H; Zang W; Mi Z; Li J; Wang L; Xie D; Zhao L; Wang D
J Control Release; 2022 Dec; 352():256-275. PubMed ID: 36272660
[TBL] [Abstract][Full Text] [Related]
8. Taxanes prodrug-based nanomedicines for cancer therapy.
Sun L; Zhao P; Chen M; Leng J; Luan Y; Du B; Yang J; Yang Y; Rong R
J Control Release; 2022 Aug; 348():672-691. PubMed ID: 35691501
[TBL] [Abstract][Full Text] [Related]
9. Zwitterion-Driven Shape Program of Prodrug Nanoassemblies with High Stability, High Tumor Accumulation, and High Antitumor Activity.
Li G; Sun B; Zheng S; Xu L; Tao W; Zhao D; Yu J; Fu S; Zhang X; Zhang H; Zhai Y; Luo C; Ding H; He Z; Sun J
Adv Healthc Mater; 2021 Dec; 10(23):e2101407. PubMed ID: 34601824
[TBL] [Abstract][Full Text] [Related]
10. Photosensitizer-driven nanoassemblies of homodimeric prodrug for self-enhancing activation and synergistic chemo-photodynamic therapy.
Zhang S; Wang Z; Kong Z; Wang Y; Zhang X; Sun B; Zhang H; Kan Q; He Z; Luo C; Sun J
Theranostics; 2021; 11(12):6019-6032. PubMed ID: 33897896
[TBL] [Abstract][Full Text] [Related]
11. Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy.
Zhong ZX; Li XZ; Liu JT; Qin N; Duan HQ; Duan XC
Int J Nanomedicine; 2023; 18():1281-1298. PubMed ID: 36945256
[TBL] [Abstract][Full Text] [Related]
12. Probing the fluorination effect on the self-assembly characteristics,
Wang X; Yang B; Li L; Liu T; Zuo S; Chi D; He Z; Sun B; Sun J
Theranostics; 2021; 11(16):7896-7910. PubMed ID: 34335971
[No Abstract] [Full Text] [Related]
13. Camptothecin-based prodrug nanomedicines for cancer therapy.
Zhang R; Yu J; Guo Z; Jiang H; Wang C
Nanoscale; 2023 Nov; 15(44):17658-17697. PubMed ID: 37909755
[TBL] [Abstract][Full Text] [Related]
14. Kinetically-stable small-molecule prodrug nanoassemblies for cancer chemotherapy.
Zheng Y; Ying X; Su Y; Jin X; Xu Q; Li Y
Int J Pharm; 2021 Mar; 597():120369. PubMed ID: 33577910
[TBL] [Abstract][Full Text] [Related]
15. Emerging carrier-free nanosystems based on molecular self-assembly of pure drugs for cancer therapy.
Zhang X; Li N; Zhang S; Sun B; Chen Q; He Z; Luo C; Sun J
Med Res Rev; 2020 Sep; 40(5):1754-1775. PubMed ID: 32266734
[TBL] [Abstract][Full Text] [Related]
16. Kinetic stability-driven cytotoxicity of small-molecule prodrug nanoassemblies.
Li Y; Chen Y; Huang Y; Wu W; Liu Y; Zhang J; Huang M; Gou M
J Mater Chem B; 2019 Sep; 7(36):5563-5572. PubMed ID: 31465067
[TBL] [Abstract][Full Text] [Related]
17. Probing the Impact of Surface Functionalization Module on the Performance of Mitoxantrone Prodrug Nanoassemblies: Improving the Effectiveness and Safety.
Zhang B; Li L; Huang M; Zhao E; Li Y; Sun J; He Z; Fu C; Liu G; Sun B
Nano Lett; 2024 Mar; 24(12):3759-3767. PubMed ID: 38478977
[TBL] [Abstract][Full Text] [Related]
18. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
[TBL] [Abstract][Full Text] [Related]
19. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
20. Emerging nanomedicines of paclitaxel for cancer treatment.
Chen Q; Xu S; Liu S; Wang Y; Liu G
J Control Release; 2022 Feb; 342():280-294. PubMed ID: 35016919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
